We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Glycemic Variability Predicts Major Adverse Cardiac Event

By LabMedica International staff writers
Posted on 19 Mar 2019
Major adverse cardiovascular events (MACE) are a composite endpoint frequently used in cardiovascular studies, comparable to the composite endpoint all-cause mortality. More...
Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which makes comparison of similar studies difficult.

Acute glucose fluctuations are associated with hypoglycemia and are emerging risk factors for cardiovascular outcomes. However, the relationship between glycemic variability (GV) and the occurrence of midterm MACE in patients with diabetes remains unclear. A glycemic variability cutoff value could be the strongest independent predictive factor for midterm MACE in patients with diabetes and acute coronary syndrome.

Medical scientists at the Centre Hospitalier Universitaire de Bordeaux (Bordeaux, France) and their colleagues investigated the relationship between glycemic variability and the occurrence of midterm MACE. The team assessed glycemic variability in 327 consecutive patients (mean age, 69 years) hospitalized with diabetes and acute coronary syndrome. Each patient was evaluated for glycemic variability at enrollment and was monitored during follow-up for such major cardiovascular events as new-onset myocardial infarction, acute heart failure, and cardiac death.

The investigators reported that of the study population, 89 (27.2%) people experienced a major cardiovascular event during a mean follow-up of 16.9 months; 24 patients died of cardiac causes, 35 had new-onset myocardial infarction, and 30 were hospitalized because of acute heart failure. Using multivariable logistic regression analysis, they found multiple independent predictive factors of midterm major cardiovascular events, including a glycemic variability value greater than 2.7 mmol/L (odds ratio [OR] = 2.21); a synergy between Percutaneous Coronary Intervention (PCI) with Taxus and Cardiac Surgery score greater than 34 (OR = 1.88), and reduced ventricular ejection fraction of less than 40%. A Global Registry of Acute Coronary Events risk score greater than 140 was not predictive (OR = 1.07).

The authors concluded that a GV cutoff value of greater than 2.70 mmol/L was the strongest independent predictive factor for midterm MACE in patients with diabetes and acute coronary syndrome. The study was published in the February 2019 issue of the journal Diabetes Care.

Related Links:
Centre Hospitalier Universitaire de Bordeaux


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.